FORTY51 VENTURES

We invest in European early stage biotech opportunities with a clear path to the clinic, whether single-asset or platform. FORTY51 Ventures is the first institutional investor in your biotech company... FORTY51 Ventures was founded in April 2022 as company builder and early stage investor of exceptional biotech companies in Europe with first or best-in-class potential. We source and incubate locally, and mature companies globally... We are therapeutic area agnostic with a preference for CNS, oncology, immunology and inflammation, fibrotic disorders and optha.